April 2020 FDA Recall Drug by B & B Pharmaceuticals, Inc.
D-1244-2020 - cGMP deviations

This Class II drug recall was voluntarily initiated by B & B Pharmaceuticals, Inc. on April 14, 2020 for the product Drug. The FDA reported the reason for recall as cgmp deviations. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-1244-2020

Reason for Recall
cGMP deviations: Presence of foreign material (Teflon)introduced at the production level.
Initiated
04-14-2020
Reported
04-22-2020
Quantity
3,825 grams

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
B & B Pharmaceuticals, Inc.
Estradiol, USP (Non-Micronized) (Hemihydrate), packaged in: a) 500 grams (NDC 63275-9900-8), b) 100 grams (NDC 63275-9900-5), c) 25 grams (NDC 63275-9900-4), Distributed by B&B Pharmaceuticals, Inc. 800-499-3100

Batch or Lot Expiration Information

Lot# : 18K26-BB02-PR00553, Reassay 10/09/2023 Product # 700365, 700362 & 700363